Toxic clozapine serum levels during inflammatory reactions

Journal of Clinical Psychopharmacology

Volumn 29, Issue 4, 2009, Pages 392-394

  Pfuhlmann, Bruno ^a   Hiemke, Christoph ^b   Unterecker, Stephan ^a   Burger, Rainer ^a   Schmidtke, Armin ^a   Riederer, Peter ^a   Deckert, Jürgen ^a   Jabs, Burkhard ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; THEOPHYLLINE;

BIOTRANSFORMATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MONITORING; ENZYME INHIBITION; HUMAN; INFLAMMATION; LETTER; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANTIPSYCHOTIC AGENTS; C-REACTIVE PROTEIN; CLOZAPINE; DRUG MONITORING; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION;

EID: 68449085751     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181acd20b     Document Type: Letter

References (14)

1. Chang KC, Lauer BA, Bell TD, et al. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet. 1978;1:1132-1133.
2. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995;272:984-990.
3. Raaska K, Raitasuo V, Arstila M, et al. Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol. 2002;58:321-322.
4. De Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1059-1063.
5. Haack MJ, Bak MLFJ, Beurskens R, et al. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol. 2003;13:381-385.
6. Jecel J, Michel TM, Gutknecht L, et al. Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol. 2005;60:909-910.
7. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104-111.
8. Baumann P, Hiemke C, Ulrich S et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
9. Iber H, Sewer MB, Barclay TB, et al. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev. 1999;31:29-41.
10. Morgan ET. Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos. 2001;29:207-212.
11. Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab. 2004;5:235-243.
12. Aitken AE, Richardsen TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46:123-149.
13. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther. 2001;92:147-163.
14. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36:205-216.